Clinical Trial Update: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) [Phase 3]

View source ↗

Summary

Phase 3 PEARL study evaluating durvalumab alone or chemotherapy in patients with advanced non-small cell lung cancer; results were posted in December 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Carcinoma NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-26